.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FE03_Necitumumab.Necitumumab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FE03_Necitumumab.Necitumumab| name: | Necitumumab |
| ATC code: | L01FE03 | route: | intravenous |
| n-compartments | 2 |
Necitumumab is a recombinant human IgG1 monoclonal antibody that binds to and inhibits the epidermal growth factor receptor (EGFR). It is used for the treatment of metastatic squamous non-small cell lung cancer (NSCLC) in combination with chemotherapy. Necitumumab was approved by the FDA in 2015 for this indication.
Pharmacokinetics reported in adult patients with advanced solid tumors and squamous NSCLC; population PK analysis.